Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Aug;62(2):250-2.
doi: 10.1111/j.1365-2125.2006.02635.x.

The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir

David M Burger, H Reinier Schwietert, E P H Colbers, Mark Becker

The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir

David M Burger et al. Br J Clin Pharmacol. 2006 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of CYP2C19 mutations on the M8/nelfinavir AUC ratio
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos. 2004;32:1462–7. - PubMed
    1. Lillibridge JH, Lee CA, Pithavala YK, Daniels RG, Samuel TM, Wu EY, Zhang KE, Mazabel EL, Zhang M, Kerr BM. The Role of Polymorphic CYP 2C19 in the Metabolism of Nelfinavir Mesylate. p. abstract 3035. 12th AAPS Conference 1998.
    1. Khaliq Y, Gallicano K, Seguin I, Fyke K, Carignan G, Bulman D, Badley A, Cameron DW. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol. 2000;50:108–15. - PMC - PubMed
    1. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20:153–67. - PubMed
    1. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004;19:83–95. - PubMed

Publication types